Market Research Logo

Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update

Summary

Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France, among others. Glaukos is headquartered in San Clemente, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Glaukos Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Glaukos Corp Company Overview 6
Glaukos Corp Company Snapshot 6
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Glaukos Corp – Pipeline Analysis Overview 8
Glaukos Corp - Key Facts 8
Glaukos Corp - Major Products and Services 9
Glaukos Corp Pipeline Products by Development Stage 10
Glaukos Corp Ongoing Clinical Trials by Trial Status 12
Glaukos Corp Pipeline Products Overview 15
GTS400 15
GTS400 Product Overview 15
iDose Travoprost Intraocular Implant 16
iDose Travoprost Intraocular Implant Product Overview 16
iDose Travoprost Intraocular Implant Clinical Trial 17
IOP Sensor System 18
IOP Sensor System Product Overview 18
iStent Infinite 19
iStent Infinite Product Overview 19
iStent Infinite Clinical Trial 20
iStent inject Trabecular Micro-Bypass Stent 21
iStent inject Trabecular Micro-Bypass Stent Product Overview 21
iStent inject Trabecular Micro-Bypass Stent Clinical Trial 22
iStent SA 25
iStent SA Product Overview 25
iStent SA Clinical Trial 26
iStent Supra Suprachoroidal Micro-Bypass Stent 30
iStent Supra Suprachoroidal Micro-Bypass Stent Product Overview 30
iStent Supra Suprachoroidal Micro-Bypass Stent Clinical Trial 31
Glaukos Corp - Key Competitors 34
Glaukos Corp - Key Employees 35
Glaukos Corp - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Glaukos Corp, Recent Developments 37
Jun 25, 2018: Glaukos’ iStent inject micro-bypass device gets FDA approval 37
May 09, 2018: Glaukos Announces First Quarter 2018 Financial Results 37
Apr 14, 2018: IDE Pivotal Trial Results for Glaukos iStent inject Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery 38
Apr 11, 2018: Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery 39
Feb 28, 2018: Glaukos Reports Fourth Quarter and Full Year 2017 Financial Results 41
Feb 28, 2018: Raysearch Laboratories: First clinic now live with RayCare 42
Feb 27, 2018: Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting 43
Feb 27, 2018: International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients 44
Feb 26, 2018: Apollo Endosurgery Announces First ORBERA U.S. Post-Approval Publication 45
Feb 08, 2018: Glaukos iStent Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study 46
Appendix 48
Methodology 48
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Tables
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Glaukos Corp Pipeline Products by Equipment Type 7
Glaukos Corp Pipeline Products by Indication 7
Glaukos Corp Ongoing Clinical Trials by Trial Status 7
Glaukos Corp, Key Facts 8
Glaukos Corp, Major Products and Services 9
Glaukos Corp Number of Pipeline Products by Development Stage 10
Glaukos Corp Pipeline Products Summary by Development Stage 11
Glaukos Corp Ongoing Clinical Trials by Trial Status 12
Glaukos Corp Ongoing Clinical Trials Summary 13
GTS400 - Product Status 15
GTS400 - Product Description 15
iDose Travoprost Intraocular Implant - Product Status 16
iDose Travoprost Intraocular Implant - Product Description 16
iDose Travoprost Intraocular Implant - A Prospective, Randomized, Phase III IND Study of iDose Travoprost in Open-angle Glaucoma Patients 17
iDose Travoprost Intraocular Implant - Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure 17
IOP Sensor System - Product Status 18
IOP Sensor System - Product Description 18
iStent Infinite - Product Status 19
iStent Infinite - Product Description 19
iStent Infinite - A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of iStent Infinite in Refractory Glaucoma Patients 20
iStent inject Trabecular Micro-Bypass Stent - Product Status 21
iStent inject Trabecular Micro-Bypass Stent - Product Description 21
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 22
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 22
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of the Second Generation iStent Inject in Open-angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications 23
iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized Evaluation of Subjects with Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated with Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 23
iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 24
iStent inject Trabecular Micro-Bypass Stent - A Randomized Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery with Insertion of iStent Inject 24
iStent SA - Product Status 25
iStent SA - Product Description 25
iStent SA - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 26
iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) 26
iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin 27
iStent SA - Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject 27
iStent SA - The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients with Glaucoma or Ocular Hypertension: An Observational Study 28
iStent SA - Trabeculectomy with MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors 28
iStent SA - US Investigational Device Exemption (IDE) Pivotal Study of iStent SA Standalone Micro-Invasive Glaucoma Surgery 29
iStent Supra Suprachoroidal Micro-Bypass Stent - Product Status 30
iStent Supra Suprachoroidal Micro-Bypass Stent - Product Description 30
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 31
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 31
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 32
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent 32
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 33
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery 33
Glaukos Corp, Key Employees 35
Glaukos Corp, Subsidiaries 36
Glossary 50
List of Figures
Glaukos Corp Pipeline Products by Equipment Type 7
Glaukos Corp Pipeline Products by Development Stage 10
Glaukos Corp Ongoing Clinical Trials by Trial Status 12

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report